Emmaus Life Sciences, Inc. (OTCMKTS:EMMA – Get Rating) fell 7% on Tuesday . The stock traded as low as $0.22 and last traded at $0.28. 35,033 shares traded hands during trading, an increase of 122% from the average session volume of 15,775 shares. The stock had previously closed at $0.30.
Emmaus Life Sciences Stock Performance
The firm has a fifty day moving average price of $0.33 and a two-hundred day moving average price of $0.36. The stock has a market capitalization of $14.97 million, a P/E ratio of -1.12 and a beta of 2.48.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc operates as a biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company was founded on March 20, 1987 and is headquartered in Torrance, CA.
Featured Articles
- Get a free copy of the StockNews.com research report on Emmaus Life Sciences (EMMA)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
